MDS-My Story...so Far! By Barry Parnas
MDS - My Story . . . so far
Myelodysplastic Syndromes (MDS)
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms
In this article we provide a practical and comprehensive review of myeloid neoplasms with overlapping myelodysplastic (MDS) and myeloproliferative (MPN) features, with emphasis on recent updates in classification, particularly the utility of morphologic, cytogenetic, and molecular findings in better defining and classifying these disease entities.
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
Most patients with lower risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A gro
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS
PURPOSE OF REVIEW:
Alleviating cytopenias, namely anemia anemia: (uh-NEE-mee-uh) A condition in which there is a shortage of red blood cells in the bloodstream. This causes a low red blood cell count.
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients
Patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes
The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
BACKGROUND:
Guadecitabine is a next-generation hypomethylating agent whose active metabolite decitabine decitabine: It works by reducing the amount of methylation in the body.
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Management of myelodysplastic syndromes after failure of response to hypomethylating agents
Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor prognosis and limited therapeutic options. Identification of patients who will respond to HMAs is challenging. Mechanisms underlying resistance to HMAs are not clear yet. Recently, absence of response has been associated with increased cell-cycle quiescence among the hematopoietic progenitor cells.